Wheeler Bio, Inc., a CDMO specializing in process development and small batch cGMP production of therapeutic antibodies, announced the closing of their Series A financing round. The company will use the funding to complete its state-of-the-art cGMP cell banking and drug substance manufacturing facility (500 L scale) in The Ziggurat, an Oklahoma City office tower. The first cGMP production batches in the new facility will begin in 3Q23. The round was co-led by Charles River Laboratories and Ec...